[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"skull-base-chordoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:skull-base-chordoma":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":5},"100507490",false,"NCT05888064","Multi-parametric Imaging in Personalized Radiotherapy","A Technical Framework for Combining Multi-parametric Imaging With Advanced Modelling in Personalized Radiotherapy","Inclusion Criteria:\n\n* Patients with histologically confirmed diagnosis of chordoma of the skull base\n* Particle therapy with curative intent\n* Karnofsky Performance status greater than or equal to 60\n* Patients with macroscopic disease detectable at pre-radiotherapy imaging\n* Patients undergoing PT with standardized treatment procedures\n* Patients who have signed the written informed consent for research\n\nExclusion Criteria:\n\n* Metastatic disease\n* Palliative treatment\n* Other malignancies with disease-free interval \\\u003C 5 years (excepting pre- cancerous lesions)\n* Pregnancy\n* Simultaneous CHT or Immunotherapy\n* Extensive metal instrumentation\u002Fimplants\n* Patients with autoimmune diseases (ADs) -including collagen-vascular (CVD) and inflammatory bowel (IBD)","ALL","18 Years",{"count":18,"type":19},35,"ESTIMATED","OBSERVATIONAL","The study consists in the retrospective and prospective collection of imaging data (along with clinical information related to treatment) of skull-base chordoma patients treated with particle therapy, to derive imaging biomarkers which, integrated with advanced mathematical models, will allow predicting treatment outcome on a multi-scale basis.",[23],"Skull Base Chordoma","RECRUITING","2024-08-20",{"date":27,"type":28},"2024-08-21","ACTUAL",{"date":30,"type":28},"2022-04-19",{"date":32,"type":19},"2025-08-18",{"name":34,"class":35},"CNAO National Center of Oncological Hadrontherapy","OTHER",""]